Celldex Therapeutics | CLDX - Operating Profit


Celldex Therapeutics reported $-73.62M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Agenus USD -13.31M 12.58M Mar/2025
Amgen USD 3.96B 464M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Celldex Therapeutics USD -73.62M 9.76M Sep/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Northwest Biotherapeutics USD -14.8M 2.66M Sep/2024
Pfizer USD 4.65B 3.99B Dec/2025
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Roche Holding CHF 9.56B 3.8B Dec/2025